- Home
- DTSS vs HOTH Comparison
DTSS vs HOTH Comparison
Compare DTSS & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- HOTH
- Stock Information
- Founded
- DTSS 2014
- HOTH 2017
- Country
- DTSS China
- HOTH United States
- Employees
- DTSS N/A
- HOTH 3
- Industry
- DTSS Computer Software: Prepackaged Software
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- HOTH Health Care
- Exchange
- DTSS Nasdaq
- HOTH Nasdaq
- Market Cap
- DTSS 16.5M
- HOTH 16.0M
- IPO Year
- DTSS N/A
- HOTH 2019
- Fundamental
- Price
- DTSS $2.05
- HOTH $1.44
- Analyst Decision
- DTSS
- HOTH Strong Buy
- Analyst Count
- DTSS 0
- HOTH 3
- Target Price
- DTSS N/A
- HOTH $4.00
- AVG Volume (30 Days)
- DTSS 49.3K
- HOTH 733.2K
- Earning Date
- DTSS 05-14-2025
- HOTH 05-12-2025
- Dividend Yield
- DTSS N/A
- HOTH N/A
- EPS Growth
- DTSS N/A
- HOTH N/A
- EPS
- DTSS N/A
- HOTH N/A
- Revenue
- DTSS $56,255,129.00
- HOTH N/A
- Revenue This Year
- DTSS N/A
- HOTH N/A
- Revenue Next Year
- DTSS N/A
- HOTH N/A
- P/E Ratio
- DTSS N/A
- HOTH N/A
- Revenue Growth
- DTSS 144.20
- HOTH N/A
- 52 Week Low
- DTSS $1.63
- HOTH $0.58
- 52 Week High
- DTSS $3.55
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- DTSS 52.48
- HOTH 62.68
- Support Level
- DTSS $1.89
- HOTH $1.17
- Resistance Level
- DTSS $1.96
- HOTH $1.34
- Average True Range (ATR)
- DTSS 0.10
- HOTH 0.10
- MACD
- DTSS 0.01
- HOTH 0.02
- Stochastic Oscillator
- DTSS 81.80
- HOTH 77.27
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).